Crossmark

Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75 mg twice daily administration

Crossref DOI link: https://doi.org/10.1186/s40780-019-0145-3

Published Online: 2019-08-01

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Akagi, Yuuki https://orcid.org/0000-0001-9015-2507
Chiba, Tatsuo

Uekusa, Shusuke

Kato, Hiroyoshi

Yamamura, Shigeo

Aoki, Yukiko

Enoki, Mizuho

Ogawara, Yuka

Kasahara, Takanori

Kimura, Yuki

Shimizu, Tadahiro

Takeishi, Aiko

Nakajima, Yuko

Kobayashi, Hideki

Sugi, Kaoru
License Information

Text and Data Mining valid from 2019-08-01

Version of Record valid from 2019-08-01
More Information

Article History

Received: 5 January 2019

Accepted: 25 June 2019

First Online: 1 August 2019

Ethics approval and consent to participate

: This multicenter retrospective cohort study was performed after having obtained approval from each hospital’s institutional review board (Delegate: Toho University Ohashi Medical Center, approval no. 15–46).

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below